Us Bancorp \De\ Tricida, Inc. Transaction History

Us Bancorp \De\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	BUY	$8.51 - $13.6 $12,569 - $20,087	1,477 Added 289.61%	1,987 $21,000
Q1 2022 May 11, 2022	BUY	$7.35 - $10.63 $727 - $1,052	99 Added 24.09%	510 $4,000
Q4 2021 Feb 11, 2022	BUY	$4.19 - $9.56 $1,722 - $3,929	411 New	411 $4,000
Q3 2021 Nov 10, 2021	SELL	$3.56 - $4.64 $1,274 - $1,661	-358 Closed	0 $0
Q2 2021 Aug 05, 2021	SELL	$3.95 - $5.41 $1,185 - $1,623	-300 Reduced 45.59%	358 $2,000
Q1 2021 Apr 28, 2021	SELL	$4.52 - $7.8 $1,572 - $2,714	-348 Reduced 34.59%	658 $3,000
Q4 2020 Feb 04, 2021	BUY	$4.37 - $9.46 $4,007 - $8,674	917 Added 1030.34%	1,006 $7,000
Q3 2020 Nov 10, 2020	BUY	$8.56 - $26.93 $761 - $2,396	89 New	89 $1,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.